To increase ovulation and pregnancy rates, human chorionic gonadotropin (HCG) is used to promote final egg maturation and ovulation in anovulatory patients with low pituitary gonadotropin (Gn) stores and in patients who are ovulatory after GnRHa downregulation. After the first follicle maturation (at least 1 dominant follicle >17 mm in diameter and an estradiol concentration of 200 pg/mL in a single mature follicle), an LH surge is required to trigger follicle rupture and release of the egg [6, 11]. Because of its higher affinity and half-life compared to LH, hCG has been the predominant choice for exogenous LH supplementation to trigger the LH surge since the era of pregnant horse serum gonadotropins (PMSG) and has been used successfully for more than 30 years [12, 13]. Exogenous intramuscular injection of 10,000 IU of HCG can produce a biological effect equivalent to a 20-fold LH peak during the natural ovulatory cycle. However, despite the use of HCG to induce ovulation starting 40 years ago, the minimum effective dose of human oogenesis has not yet been determined. The minimum effective dose is a more personalized proposition to ensure the successful triggering of follicles to release eggs while preventing the occurrence of OHSS.